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Purpose of Review 
Studies from the 1990s and early 2000s documented the utility of dobutamine echocardiography (DE) for 
prediction of functional recovery and prognosis with revascularization. The results of The Surgical 
Treatment of Ischemic Heart Failure (STICH) trial called into question the value of viability assessment 
using DE. The purpose of this review is to re-examine the literature on DE, put into context the STICH 
results, and provide insight into the current role of DE viability testing. 
 
Recent Findings 
In contrast to the results of previous nonrandomized trials, the STICH trial showed that patients with 
viability defined by nuclear perfusion imaging or DE did not have improved survival with CABG compared 
with optimal medical therapy. Viability by DE was defined as the presence of contractile reserve in > 5 
segments with baseline dysfunction. The results of DE studies published before and after initiation of the 
STICH trial suggest that the definition of viability utilized in that trial may be suboptimal for assessment 
of improvement in global function and prognosis in patients undergoing revascularization. Assessment of 
global contractile reserve using wall motion score (WMS) or ejection fraction (EF) may be superior to 
utilization of a binary definition of viability confined to assessment of contractile reserve in a fixed number 
of segments because these indices provide information on both the magnitude and extent of contractile 
reserve of the entire left ventricle (LV).  
 
Summary 
Assessment of WMS or EF with DE may be the optimal means of evaluating the impact of viability on 
prognosis. (Supplementary Digital Content (SDC) call-out) 
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Key Points: 
- The STICH trial results suggested that viability testing may not be useful for outcome assessment but 
the trial had some limitations including how viability was defined. 
- Defining viability based on a limited number of segments with contractile reserve may be insufficient for 
assessing prognosis and the benefit of revascularization. 
- Viability assessment with dobutamine echocardiography should focus on evaluation of global contractile 
reserve using wall motion score or ejection fraction.  
 
 
Introduction: 
Dobutamine is a synthetic catecholamine with potent beta-1 agonist effects originally developed as an 
intravenous agent for the acute treatment of congestive heart failure.0F1 At low doses, the agent improves 
stroke volume, lowers left atrial pressure and reduces systemic vascular resistance without causing 
substantial increases in heart rate and myocardial oxygen consumption.1F2  In the 1990s, DE was 
developed as a method for assessment of viability in patients with chronic LV systolic dysfunction. The 
presence or absence of contractile response to dobutamine enables differentiation of nonviable tissue 
with transmural or extensive nontransmural infarction from stunned or hibernating myocardium.2F3,3F4 
Hibernating myocardium may manifest small and transient increases in contractility at  low doses of 
dobutamine followed by worsening of function with higher doses of dobutamine that increase heart rate 
and myocardial oxygen consumption.4F5 In the 1990s, animal and human studies showed that the 
demonstration of contractile reserve in dysfunctional myocardium correlated with the presence of viability 
by nuclear perfusion imaging and positron emission tomography using F-18 fluorodeoxyglucose.5F6,6F7 
 
Viability Assessment Before the Surgical Treatment of Ischemic Heart Failure (STICH) Trial 
In the 1990s to early 2000s, nonrandomized retrospective studies showed that in patients with ischemic 
LV dysfunction, revascularization of those with viable myocardium was associated with better outcomes 
compared to medical therapy. In a 2002 meta-analysis by Allman et al, the annual death rate was 3.2% 
in subjects with viability who underwent revascularization compared to 16% in those with viability who 
were treated with medical therapy. The marked difference in survival was attributed both to improvement 
of ventricular function in those who were revascularized and an excess of ischemia related events in 
those treated medically. The meta-analysis also revealed that in patients without viability, revascularized 
and medically treated patients had similar annual mortality (7.7% and 6.2% respectively).7F8  
 
Defining Viability: The Controversy 
The Surgical Treatment of Ischemic Heart Failure (STICH) trial, which was initiated in 2002, randomized 
subjects who had ischemic ventricular dysfunction (EF <35%) to coronary artery bypass grafting (CABG) 
or optimal medical therapy. The results of the viability substudy reported in 2011, raised doubts about 
the utility of viability testing.8F9  In this study, patients were designated as having viability based on the 
number of segments with tracer activity on single photon emission computed tomography (SPECT), or ≥5 
dysfunctional segments exhibiting contractile reserve with dobutamine.  Viability was not an independent 
predictor of outcome and patients with viability did not have improved outcome with CABG compared to 
medical therapy. The STICH definition of viability, based on contractile reserve in a fixed number of 
segments, was derived from some previous investigations  showing that  contractile reserve in 
approximately 25% of the LV was associated with modest increases (> 5%) in ejection fraction, 
improvement in functional class, and reduction in short term mortality with revascularization.9F10,10F11,11F12,12F13 
Although contractile reserve in a fixed number of dysfunctional segments  is a  commonly accepted 
definition of viability, the limitations of a binary classification of patients as having viable or nonviable 
myocardium was pointed out in a 2002 editorial by Dr. Bonow.  He stated that binary grouping, 
“oversimplifies the complex, inter-related continua of severity of LV dysfunction, extent and severity of 
inducible ischemia and magnitude of dysfunctional but viable myocardium.”13F14 
 
The limitations of a binary, 5 segment definition of viability was shown by Meluzin et al, who correlated 
the number of segments demonstrating contractile reserve with the degree of improvement in EF and 
outcomes in patients who underwent revascularization. In patients with 2 to 5 viable segments, 
revascularization improved EF by an average of 6% (34 to 40%), but the rate of cardiac events after 
revascularization was similar to those with < 2 viable segments. In contrast, in patients with > 6 viable 
segments, mean EF improved from 35% to 47% and cardiac events were significantly lower than in the 
other two groups.14F15  In a separate report, Meluzin et al also found a strong linear correlation (r = 0.91)  
between the number of segments with contractile reserve and post-revascularization improvement in EF 
suggesting that the degree of functional improvement and presumably outcome could be better assessed 
using a more continuous measure of viability.15F16 In a more recent investigation, Joshi et al, showed that 
contractile reserve in 25% of segments did not predict EF improvement after revascularization.16F17  
 
Ejection fraction and wall motion score for assessment of viability  
Assessment of the global contractile response to dobutamine using ejection fraction (EF) and wall motion 
score (WMS) are validated alternatives to reliance on a binary, 5 segment definition of 
viability.17F18,18F19,19F20,20F21,21F22  In a 1982 investigation, Nesto et al, reported that 5 year survival in patients with 
ischemic LV dysfunction was significantly better in revascularized patients with contractile reserve, 
defined as > 10% augmentation of EF, compared to those with lesser degrees of contractile reserve 
(80% vs  33%, p <0.01). Survival was also better in the medically treated group in the presence of > 
10% augmentation of EF (75% vs 9%, p < 0.01). Patients with a > 10% augmentation of EF had a mean 
EF increase after revascularization of 17% compared with no improvement in EF in those with < 10% 
augmentation.  Nesto, et al was the first to demonstrate that assessment of global contractile reserve can 
predict post-revascularization outcome, and that improvement in long-term survival might require 
substantially larger improvements in EF than a 5% increase.23  Joshi et al, showed that > 8% 
improvement in EF with revascularization was an independent predictor of long-term survival. The 8% 
threshold was considered significant improvement in function on the basis of being twice the mean inter-
observer difference (3.7%) in EF measurement.22  
 
WMS is a well validated method for diagnostic and prognostic assessment of patients with ischemic 
dysfunction.20,21,22,25  Visual analysis of wall motion and thickening is assessed in each segment of the left 
ventricle (16 or 17 segment model). Global WMS representing the average of individual segment scores 
can be derived at baseline and at various doses of dobutamine infusion. WMS incorporates information on 
both the severity and extent of segment dysfunction. 
 
The utility of WMS as a non-dichotomous index of viability was initially reported in 2002. Low dose scores 
enabled further risk assessment of a mixed population of ischemic cardiomyopathy patients 
(revascularized and medically treated) initially risk stratified on the basis of the severity of baseline 
ventricular dysfunction.  In patients with severely reduced systolic function (resting wall score > 2.50) the 
response to low dose dobutamine distinguished lower and higher risk groups (11  vs 30% one year 
cardiac mortality). In patients with an intermediate extent of viability (low dose score 2.00 to 2.49), 
cardiac mortality was significantly lower in revascularized compared to medically treated subjects (7.5% 
vs 20.5%).26  
 
The value of low dose WMS for risk assessment of 95 patients who underwent surgical revascularization 
was assessed in a 2003 investigation. Patients had a mean EF of 33% by echocardiography, and 25% by 
contrast or nuclear angiography. Increasing low dose WMS was the most important predictor of cardiac 
death, and provided incremental prognostic value to clinical data and resting left ventricular function.  
The presence of contractile reserve in > 4 segments was not predictive of outcome. Survival 
progressively improved based on the extent of viability based on WMS. 22F23  
 
In ventricles with chronic dysfunction, myocardium that is normal, remodeled, nontransmurally injured, 
and transmurally infarcted coexists with stunned and hibernating tissue. The contractile response of all 
segments contribute to outcome since they mutually contribute to global ventricular function. 
Additionally, the extent of myocardium with transmural infarction contributes to prognosis and patients 
with extensive infarction may have poor outcomes in spite of revascularization.23F24,24F25  Figure 1 highlights a 
hypothetical example of the disparity that can occur in assessment of viability using contractile reserve in 
a limited number of segments versus wall motion score.  Patient A has severe LV systolic dysfunction at 
rest by WMS with no normal segments and extensive nonviable (nonaugmenting) myocardium. However, 
the patient has 4 segments with contractile reserve and might be classified as having “viability” if defined 
on the basis of 25% of segments with contractile reserve.  Patient B has less severe dysfunction based 
on resting WMS, and a large amount of normal myocardium along with a substantial region of transmural 
infarction. This patient would be classified as having “nonviabile” myocardium based on the absence of 
segments with contractile reserve.  Apart from the influence of stress-induced ischemia on outcome, the 
long term prognosis of patient B would be expected to be better than patient A, based on marked 
differences in the extent of normal and transmurally infarcted myocardium.  
 
Reevaluating viability testing after STICH  
Since the publication of the viability substudy results in 2011, there have been almost no further 
investigations employing DE for viability assessment. The dearth of recent investigations might imply that 
clinicians and investigators have accepted the STICH results as definitive and/or that the need for viability 
testing is declining because of expansion of alternative therapies such as mechanical assist devices. The 
viability substudy of STICH was acknowledged to have limitations (see table 1) beyond the 
echocardiographic definition of viability. The clinical impact of the viability substudy results rests on 
whether the STICH study population truly represented a population considered high risk for CABG.  A 
number of characteristics suggest otherwise: although the intent was to enroll patients with EF < 35%, 
EF could not be quantified by the core laboratory in 27% of patients and an additional 19% had EF 
measurements >35%. Furthermore, the annual mortality of 7% in medically treated patients with 
viability may be a reflection of the lower risk nature of the study population.14  A substantial proportion of 
patients enrolled in STICH, had moderate LV systolic dysfunction and extensive viable myocardium. In 
patients such as these, the impact of viability on prognosis may be outweighed by other factors including 
the extent and severity of coronary disease, and the presence and extent of ischemia.  
 
DE in the Contemporary Era   
The role of DE for assessment of viability needs to re-examined in light of the results of the STICH trial. 
EF and global WMS assessed during dobutamine infusion appear to be better measures of evaluating the 
prognostic impact of viability than assessment of contractile reserve in a limited number of segments. 
Viability testing is not needed in most patients with moderate LV dysfunction, angina and suitable 
anatomy for either surgical or percutaneous revascularization.   
 
Low dose DE may remain a useful test in patients with severe global dysfunction, heart failure symptoms 
and multivessel disease who are candidates for revascularization.  DE is a low cost modality that is widely 
available.25F26 In critically ill patients (i.e. on mechanical ventilation, with extracorporeal membrane 
oxygenation or with intra-aortic balloon pump support) that cannot be transferred out of the ICU, DE can 
be easily performed at the bedside in contrast to positron emission tomography or magnetic resonance 
imaging. Demonstration of global contractile reserve using low dose dobutamine with or without 
nitroglycerin may provide additional benefit for clinical decision making.26F27,27F28 Patients who demonstrate 
global contractile reserve may benefit from revascularization whereas patients that do not have 
substantial contractile reserve may be considered for other options such as mechanical assist device.  
 
Low dose DE has also been shown to be a useful prognostic test in patients with LV dysfunction with 
EF<35% and prolonged QRS >120ms who are candidates for cardiac resynchronization therapy (CRT). In 
a meta-analysis by Kloosterman et al, a positive response to DE defined  by either an increase in LVEF or 
improvement in WMS was associated with a higher odds ratio for CRT response. This suggests that 
patients with demonstrable contractile reserve have viability and restoring synchrony improves overall 
function.28F29 In the ViaCRT study, investigators prospectively evaluated 127 patients with LVEF ≤35% on 
optimal pharmacotherapy and QRS ≥120ms. Contractile reserve with low dose DE was detected in 18% 
of patients by WMS and in 48% of patients by EF augmentation. At one year of follow-up after CRT, 
mortality was 4.4% in patients with contractile reserve by WMS versus 19.4% in those without contractile 
reserve.29F30   
 
DE has been investigated as a method to predict recovery after left ventricular assist device (LVAD) 
implantation and to guide explantation strategies with modest benefit.30F31,31F32 Khan et al, showed that in 
patients with LVAD who had a favorable response to DE (n=9), 66% had successful explantation with no 
further hospitalizations and improvement in functional class NYHA I-II.31  DE may also be useful in 
predicting outcomes in patients with nonischemic cardiomyopathy.  Wever-Pinzon et al evaluated 
contractile reserve using DE in HIV patients to predict EF improvement and found a change of WMS of 
0.59 predicted improvement with a sensitivity of 74% and specificity of 78%.32F33 McDermott et al explored 
the utility of using DE in 59 cancer patients with LVEF <50% undergoing cardiotoxic chemotherapy to 
predict LV recovery and found 100% sensitivity and 85% specificity.33F34   
 
Conclusion: 
In contemporary practice, DE remains a useful diagnostic tool for assessment of viability in high risk 
candidates for revascularization and in other settings where determination of the extent and magnitude 
of contractile reserve can provide important information for clinical decision making. For evaluation of 
prognosis, global assessment of contractile reserve using wall motion score and ejection fraction appear 
superior to assessment of contractile reserve in a limited number of segments.  
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